Skip to content. | Skip to navigation

Personal tools

This is SunRain Plone Theme

Navigation

banner12
banner13
banner17
banner6
banner14
banner11
banner3
banner18
banner4
banner2
banner1
banner7
banner5
banner8
banner10
banner16
banner15
banner9
banner0
You are here: Home / Events / Dott. Luca Sangiorgi: "Relevance of natural history study to develop new diagnostic and therapeutic strategies for rare diseases"

Dott. Luca Sangiorgi: "Relevance of natural history study to develop new diagnostic and therapeutic strategies for rare diseases"

Istituto Ortopedico Rizzoli Responsabile Genetica medica e malattie rare ortopediche Responsabile organizzativo e scientifico Laboratorio CLIBI luca.sangiorgi@ior.it
When May 20, 2019
from 12:00 PM to 01:30 PM
Where CNR Conference Room
Contact Name
Contact Phone 081 6132 302
Add event to calendar vCal
iCal

Dr Luca Sangiorgi holds a Medical degree from the University of Bologna, a PhD in Clinical Genetics at “La Sapienza” University of Rome and a Master Degree in Research Promotion and Governance in Hospital Trusts and Local Health Units at the University of Modena and Reggio Emilia.

He has been Visiting Scientist at the Molecular Oncology Section, Paediatric Branch of the National Cancer Institute in Maryland (USA).

He is currently head of the Department of Medical Genetics and Rare Orthopaedic Diseases of the Rizzoli Orthopedic Institute in Bologna, Italy. He is coordinator of the Rizzoli Rare Disease Center and coordinates the Emilia Romagna Region Hub and Spoke Network on Rare Bone Disorders.

He is the coordinator of four National Registers of Rare Disease and of BIOGEN, the rare bone disorders biobank of the Rizzoli Institute.

He has been the Italian representative in the Assembly of Member States (AoM) of BBMRI (Biobanking and Biomolecular Resources Research Infrastructure) up to December 2018; in this time frame he has been part of the Steering Committee performing different roles including the Chair of the AoM.

He is currently the Coordinator of the BBMRI-ERIC Rare Disease Interest Group and of the Rare diseases working group of the Italian National Node of BBMRI (BBMRI.it).

Since March 2018, he is acting as Coordinator of the Telethon Network of Genetic Biobanks (TNGB).

He has acted as Alternate of the Representative of Italian Government for the Committee for Advanced Therapies (CAT) of the European Medicine Agency (EMA) up to December 2017.

Since March 2017 he is the coordinator of ERN BOND that includes 38 Centres of Excellence for the treatment of Rare Bone Disorders in 10 EU Member States.

As member of many different medical and scientific societies, he has been appointed President of Connective Tissue Oncology Society and International Skeletal Dysplasia Society.

Filed under: